vvDD-IL-9

vvDD-IL-9 is an engineered **oncolytic vaccinia virus** based on the tumor-selective vvDD backbone and armed with the **interleukin-9** transgene for intratumoral cytokine delivery in cancer immunotherapy. In preclinical colon and lung tumor models, the construct was designed to replicate in tumors, lyse malignant cells, and locally express IL-9 to remodel the tumor microenvironment. Reported effects included prolonged viral persistence, increased Th1 chemokines and antitumor effector molecules such as IFN-gamma, granzyme B, and perforin, increased CD4-positive and CD8-positive T-cell infiltration, and reduced myeloid-derived suppressor cells versus the parental virus. The publication also reported increased PD-1, PD-L1, CTLA-4, and regulatory T-cell signals, with enhanced systemic antitumor immunity and survival when combined with anti-CTLA-4 antibody in murine models. Based on the provided evidence, vvDD-IL-9 appears to be a preclinical experimental oncolytic virus program rather than an approved or clinically established product.

Other names

IL-9-expressing oncolytic vaccinia virusIL9-expressing oncolytic vaccinia virusIL 9-expressing oncolytic vaccinia virusinterleukin-9-armed oncolytic vaccinia virusinterleukin9-armed oncolytic vaccinia virusinterleukin 9-armed oncolytic vaccinia virus